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Summary: 
Aims: The DHP-18 is a widely used measure of health related quality of life in diabetes mellitus but it 
is unclear what constitutes a meaningful change in score on each domain.  The aim of this study was 
to establish estimates for the minimally important difference (MID) for each of the domains. 
 
Methods: The MID for each domain was estimated using both anchor and distribution based 
approaches which were applied to data from both the United Kingdom and France.  A range of 
anchors were tested. 
 
Results: A global health change anchor was found to be more acceptable for Type 1 diabetes than 
for Type 2.  MID estimates varied by domain, by estimation approach used, and by diabetes type.  
For Type 1 diabetes the Psychological Distress domain estimates ranged from 2.86 to 11.05, Barriers 
to Activity domain from 2.87 to 11.32 and Disinhibited Eating domain from 1.03 to 11.53.  For Type 2 
diabetes the Psychological Distress estimates ranged from 0.94 to 9.71; Barriers to Activity from 1.66 
to 9.88 and Disinhibited Eating from 0.90 to 11.64. 
 
Conclusions:  This is the first attempt to derive estimates for the MID of an English language measure 
of health related quality of life in diabetes. For Type 1 diabetes we recommend using the mean MID 
value using both approaches.  For Type 2 we recommend applying more weight to the distribution 
based estimations.  The MID values identified in this study will help clinicians and researchers using 
the DHP-18 to identify clinically meaningful change in patient reported outcomes.   
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Introduction: 
Despite the plethora of diabetes-specific patient reported outcome measures (PROM) which have been 
developed to assess the various constructs associated with the impact of living with diabetes and its 
treatment on quality of life, well-being, health status and treatment satisfaction, there remains a lack in 
understanding as to what a PROM score represents and what is a meaningful change in score.  
In addition to being valid (measure what is intended) and responsive (able to detect small but, important 
change in outcome) a PROM must also provide a score which is interpretable to enable important effects 
of treatment or intervention to be determined which are not only statistically significant, but are also of 
clinical relevance. However, when establishing  what is a clinically meaningful PROM score, we must first 
understand what is a meaningful significant change in individual patient scores and what changes in 
score correspond to being  trivial, small, moderate and large [1]. 
Although no one approach to interpreting PROM scores is perfect, the use of multiple approaches such 
as anchor- and distribution based methods is more likely to enhance our understanding of the scores of 
a particular instrument. 
In this paper we report on our findings using both anchor and distribution-based approaches to 
determine the minimally important difference (MID) of the Diabetes Health Profile (DHP-18) which is a 
multidimensional diabetes-specific quality of life (QoL) measure developed for use with people with 
Type 1 and Type 2 diabetes [2]. 
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Methods: 
Measures and anchors used 
DHP-18: 
Developed from the longer DHP-1 [3] the DHP-18 [2] consists of 18 items assessing QoL in diabetes 
across three domains: Psychological Distress (PD; 6 items), Barriers to Activity (BA; 7 items) and 
Disinhibited Eating (DE; 5 items). The domains are based on a conceptual framework which focuses on 
the emotional and behavioural impact of living with diabetes.   The raw scores for each domain are 
rescaled to a metric score between 0 and 100 which can also be converted into a norm score (with a 
mean of 50 and an SD of 10).  This enables an assessment of a score in relation to a reference group, 
sample or population.  The DHP-18 has demonstrated high levels of reliability, validity and patient 
acceptability.  It has been used in multinational clinical trials, quality of life outcome research as well as 
population surveys and clinical practice and has been completed by more than 6000 people with Type 1 
and Type 2 Diabetes.  The DHP-18 is also the diabetes-specific outcome measure selected for the UK 
Department of Health Patient Reported Outcome Measures (PROMs) Pilot for Long Term Conditions in 
Primary Care. It has also been adapted for use in 26 different languages and can be completed using a 
range of media including face to face and telephone interviews, using paper/pencil, online, and also 
electronic form. 
 
Global health change item: 
A global health change item is used as an external anchor to identify respondents who have experienced 
a small but important change.  This item assesses whether health has improved or worsened on a 5 
point Likert scale (much better (5), somewhat better (4), stayed the same (3), somewhat worse (2) or 
much worse (1)) and has previously been used as an external anchor to calculate MID estimations [4]. 
 
EQ-5D: 
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The EQ-5D [5,6] is a widely used generic preference based measure of health status across 5 dimensions 
(mobility, self-care, daily activities, pain/discomfort, and anxiety/depression) providing a single figure 
utility score (anchored on a scale of one for full health and zero for dead) for use in cost utility analysis to 
generate Quality Adjusted Life Years (QALYs).  In this study the EQ-5D was tested for use as an anchor. 
 
SF-6D: 
The SF-6D is a generic preference based measure developed by Brazier et al. [7, 8].  The classification 
system assesses health status across 6 dimensions (physical functioning, role limitations, social 
functioning, pain, mental health and vitality). A selection of the possible 18,000 health states have been 
valued to produce a single figure utility score anchored at one for full health and zero for dead, and with 
a range from 0.296 to 1. The SF-6D was tested for use as an anchor in this study. 
 
Sample data 
For the anchor based analysis a longitudinal dataset  of a community-based postal survey of  1802 
participants, aged ≥18 years of age, with positive diagnosis of Type II diabetes and on diabetes patient 
registers in primary care was used to estimate values for the MID, and the characteristics of this sample 
are displayed in Table 1 [9].  For the distribution based method a cross sectional dataset of 3476 
participants who had received insulin or treatment for hypoglycaemia during the past 3 months in 
France was also used [10].  Respondents completed a postal questionnaire investigating a range of 
factors relating to diabetes including lifestyle, medical and clinical status and HRQL.  Respondents in this 
study completed the DHP-1 but only theDHP-18 items were included in this study. 
 
Analysis: 
To determine the MID for the DHP-18, both anchor based and distribution based approaches were used 
as recommended by Revicki et al. [11]. The anchor based approach assesses change on the target 
measure in comparison to some external indicator of health or clinical change which can be a subjective 
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measure of change in global health status, a clinical indicator, or change in another instrument with 
established MID values.  Distribution based approaches were used to estimate the MID based on the 
distribution of responses within the sample.  Estimating MID values using both distribution based and 
anchor based methods allows for a more precise estimate of the true MID to be calculated.  So that 
values were available for all patient groups where the DHP-18 is used, MID estimations were derived 
separately for Type 1 and Type 2 diabetes.  
 
Anchor based approach:  
Three anchors were tested for use in this study, an external indicator of health change, the EQ-5D and 
SF-6D which both have established MID values.  Small but important change on the global health item 
was defined by a score of 2 or 4 on the 5 point Likert scale.  Patients scoring 3 were defined as reporting 
no change in health status.  The MID for the EQ-5D has been tested in a range of settings and is 
estimated as a utility score change of 0.074, with a range of 0.011 to 0.140 [12].  In this study a change in 
utility between baseline and follow up within this range was defined as a small but important change, 
with change between +/- 0 and 0.011 indicating no difference in health status across the study period.   
The MID for the SF-6D from a range of patient groups has been estimated at 0.041 with a range of 0.011 
to 0.097 [12].  A difference between baseline and follow up within this range was defined as a small but 
important change, with the score range of /-0 to 0.011 indicating no change. 
 
Initially both the metric and norm scores for the three DHP-18 domains were calculated.  To test the 
validity of the three anchors, each was correlated with the three DHP-18 metric and norm domain scores 
at baseline and follow up.   To conduct a MID analysis, a minimum correlation of 0.3 is recommended 
[11], and the correlation at follow up should be greater than the correlation at baseline.  To ensure a 
range of estimations, values for the MID were produced using two methods:  
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Method 1: The MID value was produced by calculating the mean change in each of the three DHP-18 
domains scores for patients reporting a small change in health status.  Direction of the change was 
reversed (multiplied by minus 1) for those reporting a small negative change in HRQL [4]. 
Method 2: The MID was calculated by subtracting the mean change on the DHP domains for patients 
reporting no change on the anchors from those who report minimal but important change.  As with 
method 1 the direction of the change was reversed for those reporting a small negative change in health 
status [13]. 
 
Distribution based approach: 
Three commonly used distribution based methods were employed in this study. These were the 0.2 and 
0.5 Standard Deviation (SD) and Standard Error of Measurement (SEM) estimations [14, 15].  For the 0.2 
and 0.5 SD approach the MID was calculated by multiplying the standard deviation of the three metric 
dimension scores at baseline by 0.2 or 0.5 which corresponds to testing using an effect size of 0.2 and 
0.5 respectively.  For the SEM approach the following equation was used. 
 
 
The test-retest statistic and the internal consistency statistic (Cronbach’s Alpha) were used for the 
longitudinal and cross-sectional study data respectively. The effect size statistic, which measures 
responsiveness by dividing the change between two points by the standard deviation at time point one, 
was also calculated.  Effect sizes between 0.2 and 0.5 are small, 0.5 to 0.8 are considered moderate, and 
above 0.8 large [16].    
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Results: 
Anchor based approach: 
Suitability for MID analysis (Type 1 Diabetes): 
The correlations to assess whether the global health item, EQ-5D and SF-6D were suitable external 
anchors to assess a MID in the Type 1 Diabetes population are displayed in Table 2.  For the global health 
change anchor, the overall correlation with the PD and BA domains was above the minimum 0.3 level but 
not with the DE domain.  For the EQ-5D, only the BA domain was above the minimum 0.3 level.  The 
correlation with the follow up score was greater than the baseline correlation for both the global health 
anchor and the EQ-5D.  The SF-6D correlations were not significant and below the minimum 0.3 level.  
Therefore, the SF-6D was excluded as an anchor at this stage as was the EQ-5D as only one of the 
correlations was above the minimum required level.  As the majority of the correlations between the 
global health anchor and the DHP-18 domains were above the minimum required value, the MID was 
estimated using this external indicator. 
 
Suitability for MID analysis (Type 2 Diabetes): 
The correlations to assess whether the three anchors were suitable to establish the MID in a Type 2 
Diabetes population are displayed in Table 2.  The correlations between the global health change anchor 
and the domain scores at follow up were significant but did not reach the minimum 0.3 level.  Neither the 
EQ-5D or the SF-6D displayed correlations with the follow up DHP domain scores above 0.1, and 
therefore were not used as a basis for the calculation of MID values in the Type 2 population.  To assess 
and compare the values achieved using the anchor based method for both Type 1 and Type 2 Diabetes, 
the global health change anchor was also used to estimate the MID for the Type 2 sample. 
 
Estimation of MID values for Type 1 and Type 2 Diabetes: 
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The anchor based MID estimations for the Type 1 sample and the estimations for Type 2 diabetes are 
displayed in Tables 3 & 4 respectively.   The MID values estimated for Type 1 diabetes were higher than 
for Type 2, with variance in the values across the DHP-18 domains. 
 
Distribution based approach  
The MID estimations for the distribution based approach are displayed in Table 5.  For the PD domain, 
MID estimates (when both datasets are combined) range from 4.37 to 11.05 for Type 1 diabetes and 3.88 
to 8.64 for Type 2 Diabetes.  The 0.5 SD and 1SEM estimations are of a similar magnitude.  This pattern is 
continued for both the BA (Type 1 range = 4.15 to 11.32; Type 2 range = 3.68 to 9.98) and DE (Type 1 
range = 4.62 to 11.54; Type 2 range = 4.72 to 11.64) domains.  Overall the effect sizes were found to be 
within the range regarded as small or lower (Table 6). 
 
Overall range of MID estimations 
Combining both approaches, the range of MID values reported for the PD domain are 2.86 to 11.05 (Type 
1) and 0.94 to 9.71 (Type 2). The ranges for the BA domain are 2.87 to 11.32 (Type 1) and 1.66 to 9.98 
(Type 2), and for the DE domain are 1.03 to 11.55 (Type 1) and 0.90 to 11.64 (Type 2). The MID values for 
each estimation method are displayed in Figures 1 and 2.Table 7 reports the proportion displaying small 
but important change for each of the MID estimations, and also for the mean MID value. The magnitude 
of the sensitivity of the MID values generated varies depending on the estimation approach used due to 
the distribution based MID estimations being uniformly larger than the anchor estimations. 
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Discussion 
In this study we have estimated minimally important difference (MID) values for each of the three DHP-
18 domains using both anchor and distribution based methods. For Type 1 Diabetes we recommend 
examining the full range of MID values for all 3 dimensions, and the mean MID value for each domain 
may be useful in determining those who display clinically meaningful change in HRQL.  This is because the 
anchor used correlates acceptably with the domain scores, and the proportion of patients demonstrating 
minimally important change is similar across the domains.  For Type 2 Diabetes the anchor and domain 
correlations are lower, and therefore for the PD and BA domains we recommend considering the full 
range of MID values, but applying more weight to the distribution based approach values, particularly as 
the sample size is large.  The proportion of the sample changing by the mean MID on the PD and BA 
domains is of a similar magnitude.  For the DE domain we recommend focusing on the distribution based 
MID values, as the low anchor based values impacts on the overall mean value, and therefore the 
proportion of the sample who display minimum important change according to this value is significantly 
higher.  Following these recommendations will help clinicians and researchers using the DHP-18 to 
identify clinically meaningful change in patient reported outcomes. 
 
 This is the first attempt to calculate MID values for the DHP instrument, and also the first study to report 
MID values for an English language measure of HRQL for both Type 1 and Type 2 Diabetes mellitus. MID 
values have previously been estimated for a diabetes specific HRQL instrument (DQOL) but, in a 
Taiwanese population [17].  The method of combining anchor and distribution based approaches has 
previously been used in a range of studies estimating the MID for measures of HRQL [18, 19, 20].  The 
global health change anchor used in this study was used to derive the MID for the SF-6D [4]. Other similar 
global health change anchors have been used for a range of instruments [13].  
 
 In this study, the MID values generated by the anchor and distribution based approaches vary for each 
domain, with the anchor method consistently producing MID values of a smaller magnitude than the 
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distribution method.  This demonstrates that when attempting to develop an accurate measure of the 
MID it is essential to use a range of methods to develop the estimations that will guide the assessment of 
clinically meaningful change within a group of patients.  The distribution based approach may be 
particularly valid in this study as values have been estimated on two data sources.  
 
Although   low correlations identified between the global health anchor and a number of the DHP 
domains across both Type 1 and Type 2 Diabetes, the correlations were larger at the follow up time point 
than at baseline which is expected when estimating the MID [11].  For the Type 1 Diabetes sample, the 
anchor reached the minimum correlation for the PD and BA domains but not for the DE domain. The 
finding of a low correlation between the global health indicator and the DE domain can be possibly 
explained by the fact that disinhibited eating behaviour is unlikely to impact on perceived general health 
change. This would indicate that when estimating the true MID value for DE domain, more weight should 
be applied to the distribution based estimations.    However, further research is required using a more 
sensitive indicator of change which is more closely related to the disinhibited concept.        
 
For the Type 2 Diabetes group, none of the correlations reached the minimum level, suggesting more 
weight should be given to the distribution based estimations.  The EQ-5D and SF-6D were not used as 
anchors as the correlations with the DHP-18 dimensions were consistently below the recommended 
level.  This may be because the generic measures are measuring health status rather than diabetes-
specific behavioural and psychological elements that are measured by the DHP-18. This highlights the 
need for further work to investigate the relationship between health status measures such as the EQ-5D 
and condition specific instruments such as the DHP-18 in more detail and which would help to inform  
decisions around which measures to use in diabetes research and clinical practice. 
 
The MID estimations also varied between the Type 1 and Type 2 Diabetes populations.  However the size 
of the samples for each diabetes type differed substantially, and future work should estimate MID values 
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on a larger Type 1 Diabetes group as well as validate the estimations derived here as part of studies 
where the DHP-18 is used  alongside potential anchors.  
 
In conclusion, we have estimated values for the MID of the DHP-18 using different samples and both 
anchor and distribution based approaches.  Using the MID values developed in this study will assist both 
researchers and clinician who are using the DHP-18 instrument as part of their assessment of both Type 1 
and Type 2 patients with diabetes mellitus.  
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Table 1: Participant characteristics 
 Longitudinal Cross sectional 
Overall n 1802 3476 
Age (m, sd) 65.60 (11.89) 63.20 (12.42) 
Age (range)   
18-45 106 (5.9) 300 (8.6) 
46-60 459 (25.7) 1044 (30.0) 
61-70 567 (31.7) 1131 (32.5) 
71-80 480 (26.8) 836 (24.1) 
81+  177 (9.9) 165 (4.7) 
Gender   
Male  1056 (58.8) 1900 (54.7) 
Female 739 (41.2) 1576 (45.3) 
Type   
Type I 143 (97.9) 231 (6.8) 
Type 2  1613 (89.5) 3156 (93.2) 
DHP-18 scores (baseline)  
PD  19.76 (21.50) 20.53 (19.34) 
BA 23.32 (19.86) 23.99 (18.38) 
DE 36.03 (23.03) 33.46 (23.81) 
DHP-18 scores (follow up)  
PD  18.82 (21.35) - 
BA 23.37 (20.41) - 
DE 35.80 (22.62) - 
EQ-5D score (baseline) 0.644 (0.32) - 
EQ-5D score (follow up) 0.639 (0.33) - 
SF-6D score (baseline) 0.687 (0.16) - 
SF-6D score (follow up) 0.682 (0.16) - 
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Table 2: Correlations between the anchors and the baseline/follow up domain scores for Type 1 
and Type 2 Diabetes (longitudinal data only, anchors used in bold) 
 Psychological distress Barriers to activity Disinhibited eating 
 Baseline 
(n) 
Follow up 
(n) 
Baseline 
(n) 
Follow up 
(n) 
Baseline 
(n) 
Follow up 
(n) 
Type 1 Diabetes (Metric/Norm score)       
Global health change anchor       
 0.183 
(99) 
0.348* 
(98) 
0.232** 
(99) 
0.369* 
(99) 
0.052 
(99) 
0.079 
(98) 
EQ-5D       
 0.045 
(95) 
0.223** 
(94) 
0.179 
(95) 
0.308* 
(94) 
0.122 
(95) 
0.088  
(94) 
SF-6D       
 -0.124 
(100) 
0.081  
(99) 
0.042 
(100) 
0.172  
(99) 
-0.139 
(100) 
-0.011  
(99) 
Type 2 Diabetes (Metric/Norm score)       
Global health change anchor       
 0.146* 
(1158) 
0.185* 
(1130) 
0.127* 
(1155) 
0.202* 
(1129) 
0.026 
(1156) 
0.111* 
(1130) 
EQ-5D       
 -0.084* 
(1100) 
0.035 
(1079) 
-0.078* 
(1095) 
0.017 
(1076) 
0.092 
(1096) 
0.033 
(1080) 
SF-6D       
 -0.071 
(75) 
0.026  
(75) 
-0.050 
(75) 
0.045  
(75) 
-0.142 
(75) 
-0.024  
(75) 
* significant at 0.01 level; ** significant at 0.05 level 
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Table 3: MID values for anchor based methods (Type 1 sample) 
Anchor n Psychological distress  Barriers to activity Disinhibited eating 
Method 1 M, SD 95% CI M, SD 95% CI M, SD 95% CI 
Metric score       
Global health   33 -5.72 (18.08) -11.89 to 0.45 -6.06 (18.91) -12.51 to 0.39 -2.22 (15.24) -7.42  to 2.98 
Norm score       
Global health  33 -2.86 (8.58) -5.79 to 0.09 -2.87 (9.31) -5.98 to 0.38 -1.03 (6.71) -3.32 to 1.26 
Method 2       
Metric score        
Global health  88 7.67 (17.45) 4.02 to 11.32 6.61 (15.70) 3.33 to 9.89 6.46 (14.42) 3.45 to 9.47 
Norm score       
Global health  88 4.25 (8.23) 2.53 to 5.97 3.00 (7.75) 1.38 to 4.62 3.00 (6.36) 1.67 to 4.33 
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Table 4: MID values for anchor based methods (Type 2 sample) 
Anchor  Psychological distress Barriers to activity Disinhibited eating 
Method 1 M, SD 95% CI M, SD 95% CI M, SD 95% CI 
n 336  336  337  
Metric score       
Global health  -1.73 (15.73) -3.41 to -0.05 -3.48 (15.21) -5.11 to -1.85 -1.95 (17.39) -3.81 to -0.09 
Norm score       
Global health  -0.94 (7.34) -1.72 to -0.16 -1.66 (7.55) -2.48 to -0.85 -0.90 (7.61) -1.71 to -0.09 
Method 2       
n                  1032 1029  1033  
Metric score        
Global health  1.37 (14.67) 0.47 to 2.27 3.94 (13.90) 3.09 to 4.79 1.85 (16.36) 0.85 to 2.85 
Norm score       
Global health  1.20 (6.85) 0.78 to 1.65 1.92 (6.91) 1.50 to 2.34 0.95 (7.16) 0.51 to 1.39 
Nb. Effect size calculated as Change between baseline and follow up / SD at baseline 
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Table 5: MID values for Type 1 and 2 diabetes (distribution based method) 
Level Psychological 
distress 
Barriers to 
activity 
Disinhibited 
eating 
Type 1 Diabetes   
 UK data   
n 143 142 142 
0.2 SD 4.78 4.02 4.49 
0.5 SD 11.95 10.1 11.22 
1 SEM 12.19 10.69 10.14 
French data    
n 230 222 222 
0.2 SD 4.11 4.23 4.69 
0.5 SD 10.28 10.57 11.73 
1 SEM 9.35 11.72 11.24 
Overall MID (both 
datasets) 
   
n 373 364 364 
0.2 SD 4.37 4.15 4.62 
0.5 SD 10.92 10.39 11.53 
1 SEM 11.05 11.32 10.81 
Type 2 Diabetes   
UK data   
n 1604 1603 1604 
0.2 SD 4.14 3.84 4.62 
0.5 SD 10.35 9.60 11.54 
1 SEM 10.55 9.79 11.54 
French data   
n 3075 2958 2953 
0.2 SD 3.75 3.59 4.77 
0.5 SD 9.38 8.98 11.92 
1 SEM 7.64 10.08 11.69 
Overall MID (both 
datasets) 
   
n 4679 4561 4557 
0.2 SD 3.88 3.68 4.72 
0.5 SD 9.71 9.20 5.8 
1 SEM 8.64 9.98 11.64 
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Table 6: Effect size statistics 
 Psychological 
distress 
Barriers to 
activity 
Disinhibited 
eating 
Type I    
Method 1 0.23 0.30 0.10 
Method 2 0.32 0.33 0.29 
Type 2    
Method 1 0.08 0.18 0.08 
Method 2 0.07 0.21 0.08 
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Table 7: MID summary table and the sample proportion reporting minimally important change  
 Psychological 
distress 
Barriers to activity Disinhibited eating 
 MID Proportion 
reporting 
change (%) 
MID Proportion 
reporting 
change (%) 
MID Proportion 
reporting 
change (%) 
Type 1       
Anchor       
Method 1 2.86 57.4 2.87 59.0 1.03 77.0 
Method 2 4.25 47.5 3.00 57.4 3.00 54.9 
Distribution       
0.2 SD 4.37 47.5 4.15 57.4 4.62 45.9 
0.5 SD 10.92 10.7 10.39 18.9 11.53 14.8 
1 SEM 11.05 10.7 11.32 18.9 10.81 14.8 
Mean MID 6.69 30.3 6.35 37.7 6.19 28.9 
Type 2       
Anchor       
Method 1 0.94 66.8 1.66 75.2 0.90 79.4 
Method 2 1.20 66.8 1.92 75.2 0.95 79.4 
Distribution       
0.2 SD 3.88 40.5 3.68 46.6 4.72 45.8 
0.5 SD 9.71 15.1 9.20 18.4 5.8 38.7 
1 SEM 8.64 15.3 9.98 12.4 11.64 11.0 
Mean MID 4.87 32.6 5.29 29.9 2.80 71.2 
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Figure 1: MID values for Type I diabetes 
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Figure 2: MID values for Type 2 Diabetes 
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